Multipl sklerozda akut atak dönemlerinde nörofilament hafif zincir düzeylerinin değerlendirilmesi

Year 2024, Volume: 49 Issue: 4, 901 - 907, 30.12.2024

Alp Sarıteke , Levent Öcek , İnanç Karakoyun , Ayfer Çolak , Ufuk Şener

https://doi.org/10.17826/cumj.1463251

Abstract

Amaç: Bu çalışmanın amacı, multipl skleroz (MS) hastalarında serum nörofilament hafif zincir (sNfL) düzeylerinin atak tedavisi öncesi ve sonrasında akut dönemde nasıl etkilendiğinin incelenmesi ve klinik bulgular ile ilişkisinin değerlendirilmektir.
Gereç ve Yöntem: Aralık 2019-Kasım 2020 tarihleri arasında kesin olarak relapsing-remitting MS (RRMS) tanısı olan ve klinik atak geçiren 38 hasta çalışmaya dahil edildi. Hastaların demografik ve klinik verileri kayıt altına alındı. Atak öncesi ve tedavisi sonrasındaki sNfL düzeyleri çalışıldı. sNfL düzeylerinin hastaların klinik özellikleri ve atak tedavisi ile ilişkisi analiz edildi.
Bulgular: Toplam 38 RRMS hastasını sNfL örnekleri değerlendirildi. Hastaların yaş ortalaması 35.8 ± 9.68 yıl (19 – 55 yıl) idi. Hastaların atak tedavi öncesinde ortanca sNfL düzeyi 3.55 pg/mL (3.09 – 4.54 pg/mL), sonrasında ise 3.36 pg/mL (3.01 – 3.86 pg/mL) idi. Atak tedavisi öncesi ve sonrasındaki sNfL düzeyleri arasında istatistiksel olarak anlamlı fark saptanmadı. Atak tedavisi öncesi ve sonrasındaki sNfL düzeyleri ile hastaların cinsiyet, yaş, hastalık süresi gibi klinik bulgular ve laboratuvar bulguları arasında anlamlı ilişki gösterilemedi. Atak tedavisi sonrasında immünglobülin G indeksi yüksek olan grupta sNfL düzeyinin daha fazla azaldığı gösterildi, ancak istatistiksel anlamlık saptanmadı.
Sonuç: Prognostik ve uzun dönemde nöronal dejenerasyon belirteci olan sNfL’in yüksek doz kortikosteroid tedavisinden etkilenmediği çalışmamızda gösterilmiştir.

Keywords

Atak tedavisi, Kortikosteroid, Multipl skleroz, Nörofilament, Nörofilament hafif zincir

Evaluation of neurofilament light chain levels in multiple sclerosis during acute attack periods

Abstract

Purpose: The aim of this study is to evaluate how the serum neurofilament light chain (sNfL) was influenced in the multiple sclerosis (MS) patients before and after treatment of an acute attacks, and to determine the relationship of it with clinical findings.
Materials and Methods: Thirty eight patients with a definite diagnosis of relapsing-remitting MS (RRMS) and who had a clinical acute attack between December 2019 and November 2020 were included in the study. The sNfL levels were studied before and after the treatment of an acute attacks. The relationship of sNfL levels with the patients’ clinical characteristics and treatment of acute attack was analyzed.
Results: The sNfL levels of a total of 38 RRMS patients were evaluated. The mean age of the patients were 35.8 ± 9.68 years (19-55 years). The sNfL level before and after treatment of acute attack were 3.55 pg/mL (3.09-4.54 pg/mL) and 3.36 pg/mL (3.01-3.86 pg/mL), respectively. No statistically significant difference was found between the sNfL levels before and after treatment. Likewise, no relationship between the before and after treatment sNfL levels with clinical findings such as gender, age, duration of disease, and biochemical findings were detected.
Conclusion: In our study, we found that the sNfL level, which is a biomarker of the prognosis and neuronal degeneration in the long-term, did not influenced by the high dose corticosteroid treatment.

Keywords

Attack treatment, Corticosteroid, Multiple Sclerosis, Neurofilament, Neurofilament Light Chain

References

• Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:1613-5.
• Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol 2014;13:113-26.
• Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012;18:552-6.
• Castle D, Wynford Thomas R, Loveless S, Bentley E, Howel OW, Tallantyre EC. Using biomarkers to predict clinical outcomes in multiple sclerosis. Pract Neurol. 2019;19:342-9.
• Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655-61.
• Rosso M, Gonzalez CT, Healy BC, Saxena S, Paul A, Bjornevik K et al. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020;7:945-55.
• Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017;5:e422.
• Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, Radaelli M et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019;92:733-41.
• Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92:1007-15
• Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25:678-86.
• Gawde S, Agasing A, Bhatt N, Toliver M, Kumar G, Massey K et al. Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022;63: 103922..
• Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al . Diagnostic criteria for multiple sclerosis: 2010 revisions McDonald criteria. Ann Neurol. 2011;69:292-302.
• Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T et al. International Clinically Isolated Syndrome Study Group. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016;87:126-9.
• Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016;22:1550-59.
• Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141:1085-93.
• Domingues RB, Fernandes GBP, Leite FBVM, Senne C. Neurofilament light chain in the assessment of patients with multiple sclerosis. Arq Neuropsiquiatr. 2019;77:436-41.
• Bergman J, Dring A, Zetterberg H, Blennow K, Norgren N, Gilthorpe J et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016;3:1-7.
• Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10:51-66.
• Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño JC et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035-48.
• Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69:83-9.
• Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015;84:1639-43.
• Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C et al Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017;23:62-71.
• Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B et al. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. Mult Scler. 2019;25:937-46.
• Engel S, Steffen F, Uphaus T, Scholz-Kreisel P, Zipp F, Bittner S et al. Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e679.
• Uher T, McComb M, Galkin S, Srpova B, Oechtering J, Barro C et al. Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult Scler. 2021;27:220-31.